|
Market Closed -
NYSE
21:00:00 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.9710 USD | -5.73% |
|
-5.73% | -41.86% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 260.5 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -35.63% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 260.5 | 260.5 | 260.5 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -35.63% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -17.2x | -8.03x | 32.5x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0x | -0x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 17.1x | 15.5x | 4.36x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 17.1x | 15.5x | 4.36x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -7.74x | -8.86x | -8.5x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.21x | -7.4x | 39.7x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -21x | -27.9x | 84x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -4.76% | -3.59% | 1.19% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.06 | -0.1283 | 0.0317 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 15.19 | 16.83 | 59.72 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -33.64 | -29.41 | -30.66 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -31.71 | -35.22 | 6.562 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -22.64 | -34.44 | 8.605 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.030 | 1.030 | 1.030 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 252,907 | - | - |
| Announcement Date | 10/03/22 | 09/03/23 | 07/03/24 | 10/03/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.17x | - | - | - | 260M | |
| 33.26x | 5.97x | 17.88x | 0.98% | 47.97B | |
| 34.82x | 3.35x | 14.46x | -.--% | 44.5B | |
| -21.07x | 227.64x | -22.77x | -.--% | 43.93B | |
| 47.27x | 5.47x | 29.96x | -.--% | 41.03B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.85B | |
| 35.19x | 5.78x | 26.24x | -.--% | 17.27B | |
| -61.04x | 9.99x | 243.78x | -.--% | 15.34B | |
| 25.79x | 2.21x | 9.6x | 1.04% | 15.3B | |
| Average | 11.55x | 33.52x | 42.38x | 0.3% | 28.39B | |
| Weighted average by Cap. | 19.66x | 43.80x | 26.11x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
